Nabi Bipharmaceuticals Finally Buckles: Activist Shareholders to Join Board
13th Nov 2006, 22:53 GMT
Lon Juricic submits:, Nabi Biopharmaceuticals and dissident shareholder 3rd Point announced that they have reached a settlement relating to a potential consent solicitation.
Nabi Bipharmaceuticals Finally Buckles: Activist Shareholders to Join Board related news:
- Nabi, 3rd Point agree to board changes — Financial News News from StratCenter.com
- Nabi, Third Point agree to board changes — Latest news from South Florida Business Journal
- Nabi Pharmaceuticals, Hedge Fund Reach Deal on Directors, Chairman — RedOrbit News - Health
- Shareholders turn against Telstra — The Sydney Morning Herald Business Headlines
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement — Bio-Technology News from StratCenter.com
- Shareholders play poker in front of an electronic board inside ... — World Photos on Yahoo! News Photos
- Eaton Vance Credit Opportunities Fund Annual Meeting of Shareholders — DBusiness News - Boston
- 3M Board Declares Quarterly Dividend — Nachrichten Ticker - www.finanzen.net
- A South Korean activist holds a placard during a rally in front ... — World Photos - AFP on Yahoo! News Photos
- Rajat Gupta on Goldman Sachs board — The Times Of India - India Business
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress